Conversely, in patients with B3 thymoma and thymic carcinoma, although PD-L1 expression correlates positively with higher tumor TMB, it does not significantly impact the response rate to avelumab and axitinib (110). The gene discussed is CD274; the disease is thymic carcinoma.